← FDA DRUG APPROVALS

FDA ANDA · ANDA040780

HYDROCHLOROTHIAZIDE

Sponsor: AUROBINDO PHARMA

APPLICATION
ANDA040780
TYPE
ANDA
ORIGINAL APPROVAL
2007-07-20
LATEST ACTION
2020-08-20
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

HYDROCHLOROTHIAZIDEPrescription
HYDROCHLOROTHIAZIDE 50MG · TABLET · ORAL
HYDROCHLOROTHIAZIDEPrescription
HYDROCHLOROTHIAZIDE 25MG · TABLET · ORAL

Approval history

2020-08-20Labeling · Supplement 20 · standardAP
2014-01-22Labeling · Supplement 9AP
2012-01-19Labeling · Supplement 12AP
2007-07-20OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →